Endotheliopathy: a continuum of hemolytic uremic syndrome due to mitomycin therapy

• Published in: American journal of kidney diseases Vol. 29; no. 2; p. 280
• Main Authors: Groff, J A, Kozak, M, Boehmer, J P, Demko, T M, Diamond, J R
• Format: Journal Article
• Language: English
• Published: United States 01-02-1997
• Subjects: Adult; Antibiotics, Antineoplastic - adverse effects; Endothelium, Vascular - pathology; Hemolytic-Uremic Syndrome - chemically induced; Hemolytic-Uremic Syndrome - complications; Hemolytic-Uremic Syndrome - pathology; Hemolytic-Uremic Syndrome - therapy; Humans; Male; Mitomycin - adverse effects; Renal Dialysis; Vascular Diseases - complications; Vascular Diseases - pathology
• DOI: 10.1016/S0272-6386(97)90042-1
• ISSN: 0272-6386

Hemolytic uremic syndrome (HUS) is a rare, often fatal complication of mitomycin C therapy. It is generally accepted that HUS is, in part, caused by endothelial cell dysfunction. Endothelial cells modulate blood flow, blood pressure, and myointimal proliferation. Endothelial cells synthesize and release products that modulate vascular tone and regulate vascular smooth muscle cell growth. We describe a patient who developed HUS secondary to mitomycin C, resulting in end-stage renal disease and necessitating chronic hemodialysis. Over several months, the patient subsequently developed multisystem organ failure involving the heart, liver, and intestine that was associated with angiographically documented small, distal vessel occlusive disease and ultrasonographically identified coronary artery intimal hyperplasia. We propose that a diffuse ongoing endothelial cell dysfunction (ie, endotheliopathy) is the putative mechanism for this patient's clinical course. To our knowledge, this continuum of HUS presenting as a multisystem, progressive disorder has not been previously reported.